Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05162443
Title Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
Recruitment Approved for marketing
Gender both
Phase Expanded access
Variant Requirements No
Sponsors Mirati Therapeutics Inc.
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
California Pacific Medical Center San Francisco California 94115 United States Details
Providence Medical Group Santa Rosa - Cancer Center Santa Rosa California 95403 United States Details
Hartford Hospital Hartford Connecticut 06106 United States Details
Piedmont Cancer Institute Atlanta Georgia 30318 United States Details
Mayo Clinic - Rochester Rochester Minnesota 55905 United States Details
Renown Health Reno Nevada 89502 United States Details
Lehigh Valley Cancer Institute Allentown Pennsylvania 18103 United States Details
Lumi Research Kingwood Texas 77339 United States Details
Virginia Cancer Institute Richmond Virginia 23230 United States Details
Seattle Integrative Cancer Center Renton Washington 98057 United States Details
Swedish Cancer Institute Seattle Washington 98104 United States Details
*Shaded cells indicate that there was no data available from for the field